Observational study reports a 74% 30-day survival rate with eravacycline for complicated infections, indicating viable therapeutic efficacy and high tolerability.
Eravacycline (ERV) was used in 35 patients for various infections. The most common pathogen was Klebsiella pneumoniae, and 30-day survival was 74%. Absence of 30-day recurrence and resolution of signs and symptoms of infection were 91% and 57%, respectively. ERV was well-tolerated, with adverse events leading to drug discontinuation in one patient.
No takes yet. Share an insight, caveat, or question.
Alosaimy et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: